Detailed introduction to the efficacy and indications of neratinib (neratinib) in the treatment of early breast cancer

Neratinib (Neratinib) is an oral, small molecule irreversible HER2/EGFR tyrosine kinase inhibitor, mainly targeted at patients with HER2 positive breast cancer. It blocks the proliferation and survival signals of tumor cells by inhibiting the HER2 and EGFR signaling pathways, thereby effectively inhibiting tumor growth. Neratinib is approved for use in patients with early-stage HER2-positive breast cancer as a postoperative adjuvant treatment. It is especially suitable for continued use after completion of trastuzumab treatment to reduce the risk of recurrence.

Multiple clinical studies have shown that neratinib has significant efficacy in the adjuvant treatment of earlyHER2 positive breast cancer. For example, the famous ExteNET study showed that the disease-free survival rate (DFS) of patients treated with neratinib was significantly better than that of the control group, especially in patients who completed trastuzumab treatment. The risk of recurrence was significantly reduced. This therapy effectively prolongs the patient's recurrence-free survival time and is of great significance in improving long-term prognosis.

Neratinib is mainly suitable for patients who have completed trastuzumab-based adjuvant therapy for early-stage HER2 positive breast cancer. It is usually started within 1 year after surgery. The drug is suitable for adult patients, especially those who are at higher risk of relapse and require intensive adjuvant therapy. At the same time, it can also be considered to extend the treatment time and improve the cure rate in high-risk patients.

Although neratinib is effective, common side effects include diarrhea, nausea and other gastrointestinal reactions. Patients need to use it under the guidance of a doctor, and may need to use anti-diarrheal drugs to prevent and alleviate side effects. In the future, as more clinical trials are conducted, neratinib is expected to play a greater role in the adjuvant treatment of breast cancer, and will be combined with other targeted or immunotherapy drugs to provide patients with a more comprehensive treatment plan.

Reference materials:https://www.drugs.com/